Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1993 Oct 2;307(6908):828–832. doi: 10.1136/bmj.307.6908.828

Radioiodine treatment of multinodular non-toxic goitre.

B Nygaard 1, L Hegedüs 1, M Gervil 1, H Hjalgrim 1, P Søe-Jensen 1, J M Hansen 1
PMCID: PMC1678858  PMID: 8401123

Abstract

OBJECTIVE--To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre. DESIGN--Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a minimum of 12 months (median 48 months) after an intended dose of 3.7 MBq/g thyroid tissue corrected to a 100% uptake of iodine-131 in 24 hours. PATIENTS--69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences. The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on. MAIN OUTCOME MEASUREMENTS--Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year. RESULTS--56 patients were treated with a single dose of 131I, 12 with two doses, and one with four doses. In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 (23-48) ml at 24 months in the 39 patients in whom this was measured during follow up. The median reduction was 40 (22-48) ml (60% reduction, p < 0.0001), half of which occurred within three months. Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume. Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4.8% to 38.4%). Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis. Only one patient was dissatisfied with the result; she was referred for operation six months after treatment. CONCLUSIONS--A substantial reduction in thyroid volume accompanied by a low incidence of hypothyroidism and few side effects makes the use of radioactive iodine an attractive alternative to surgery in selected cases of non-toxic multinodular goitre.

Full text

PDF
832

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agerbaek H., Pilegaard H. K., Watt-Boolsen S., Spangsberg N., Madsen M. R., Laursen C. N., Blichert-Toft M. Komplikationer ved 2,028 operationer for benign thyreoideasygdom. Forskellige risikofaktorers kvantitative betydning. Ugeskr Laeger. 1988 Feb 29;150(9):533–536. [PubMed] [Google Scholar]
  2. BEAHRS O. H., VANDERTOLL D. J. COMPLICATIONS OF SECONDARY THYROIDECTOMY. Surg Gynecol Obstet. 1963 Nov;117:535–539. [PubMed] [Google Scholar]
  3. Berghout A., Wiersinga W. M., Drexhage H. A., Smits N. J., Touber J. L. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet. 1990 Jul 28;336(8709):193–197. doi: 10.1016/0140-6736(90)91730-x. [DOI] [PubMed] [Google Scholar]
  4. Farrar J. J., Toft A. D. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 1991 Sep;35(3):207–212. doi: 10.1111/j.1365-2265.1991.tb03523.x. [DOI] [PubMed] [Google Scholar]
  5. Geerdsen J. P., Frølund L. Recurrence of nontoxic goitre with and without postoperative thyroxine medication. Clin Endocrinol (Oxf) 1984 Nov;21(5):529–533. doi: 10.1111/j.1365-2265.1984.tb01391.x. [DOI] [PubMed] [Google Scholar]
  6. Gharib H., James E. M., Charboneau J. W., Naessens J. M., Offord K. P., Gorman C. A. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med. 1987 Jul 9;317(2):70–75. doi: 10.1056/NEJM198707093170202. [DOI] [PubMed] [Google Scholar]
  7. Haas V., Marley M., Green A., Date J., Blichert-Toft M., Mogensen E. F. Urinary iodine excretion in a geographically stratified Danish population sample not affected by iodination programmes. A change towards higher values. Acta Endocrinol (Copenh) 1988 Sep;119(1):125–131. doi: 10.1530/acta.0.1190125. [DOI] [PubMed] [Google Scholar]
  8. Hall P., Boice J. D., Jr, Berg G., Bjelkengren G., Ericsson U. B., Hallquist A., Lidberg M., Lundell G., Mattsson A., Tennvall J. Leukaemia incidence after iodine-131 exposure. Lancet. 1992 Jul 4;340(8810):1–4. doi: 10.1016/0140-6736(92)92421-b. [DOI] [PubMed] [Google Scholar]
  9. Hansen J. M., Skovsted L., Siersbaek-Nielsen K. Age dependent changes in iodine metabolism and thyroid function. Acta Endocrinol (Copenh) 1975 May;79(1):60–65. doi: 10.1530/acta.0.0790060. [DOI] [PubMed] [Google Scholar]
  10. Hegedüs L., Hansen B. M., Knudsen N., Hansen J. M. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ. 1988 Sep 10;297(6649):661–662. doi: 10.1136/bmj.297.6649.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hegedüs L., Hansen J. M., Veiergang D., Karstrup S. Does prophylactic thyroxine treatment after operation for non-toxic goitre influence thyroid size? Br Med J (Clin Res Ed) 1987 Mar 28;294(6575):801–803. doi: 10.1136/bmj.294.6575.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hegedüs L., Karstrup S., Rasmussen N. Evidence of cyclic alterations of thyroid size during the menstrual cycle in healthy women. Am J Obstet Gynecol. 1986 Jul;155(1):142–145. doi: 10.1016/0002-9378(86)90098-0. [DOI] [PubMed] [Google Scholar]
  13. Hegedüs L., Perrild H., Poulsen L. R., Andersen J. R., Holm B., Schnohr P., Jensen G., Hansen J. M. The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects. J Clin Endocrinol Metab. 1983 Feb;56(2):260–263. doi: 10.1210/jcem-56-2-260. [DOI] [PubMed] [Google Scholar]
  14. Hegedüs L., Veiergang D., Karstrup S., Hansen J. M. Compensated 131I-therapy of solitary autonomous thyroid nodules: effect on thyroid size and early hypothyroidism. Acta Endocrinol (Copenh) 1986 Oct;113(2):226–232. doi: 10.1530/acta.0.1130226. [DOI] [PubMed] [Google Scholar]
  15. Holm L. E., Hall P., Wiklund K., Lundell G., Berg G., Bjelkengren G., Cederquist E., Ericsson U. B., Hallquist A., Larsson L. G. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991 Aug 7;83(15):1072–1077. doi: 10.1093/jnci/83.15.1072. [DOI] [PubMed] [Google Scholar]
  16. Jarløv A. E., Faber J., Hegedüs L., Hansen J. M. Subtle changes in serum thyrotrophin (TSH) and sex-hormone-binding globulin (SHBG) levels during long-term follow-up after radioactive iodine in multinodular non-toxic goitre. Clin Endocrinol (Oxf) 1992 Oct;37(4):335–337. doi: 10.1111/j.1365-2265.1992.tb02334.x. [DOI] [PubMed] [Google Scholar]
  17. KEIDERLING W., EMRICH D., HAUSWALDT C., HOFFMANN G. ERGEBNISSE DER RADIOJOD-VERKLEINERUNGSTHERAPIE EUTHYREOTER STRUMEN. Dtsch Med Wochenschr. 1964 Mar 6;89:453–457. doi: 10.1055/s-0028-1111038. [DOI] [PubMed] [Google Scholar]
  18. Kay T. W., d'Emden M. C., Andrews J. T., Martin F. I. Treatment of non-toxic multinodular goiter with radioactive iodine. Am J Med. 1988 Jan;84(1):19–22. doi: 10.1016/0002-9343(88)90003-4. [DOI] [PubMed] [Google Scholar]
  19. Klein B., Klein E., Horster F. A. Ergebnisse der fraktionierten Radiojodtherapie bei 696 Hyperthyreosen und 690 blanden Strumen. Nuklearmedizin. 1989 Aug;28(4):129–136. [PubMed] [Google Scholar]
  20. Perrild H., Hansen J. M., Hegedüs L., Rytter L., Holm B., Gundtofte E., Johansen K. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh) 1982 Jul;100(3):382–387. doi: 10.1530/acta.0.1000382. [DOI] [PubMed] [Google Scholar]
  21. Verelst J., Bonnyns M., Glinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinol (Copenh) 1990 Apr;122(4):417–421. doi: 10.1530/acta.0.1220417. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES